A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease. / Nassan, Feiby L; Coull, Brent A; Skakkebaek, Niels E; Williams, Michelle A; Dadd, Ramace; Mínguez-Alarcón, Lidia; Krawetz, Stephen A; Hait, Elizabeth J; Korzenik, Joshua R; Moss, Alan C; Ford, Jennifer B; Hauser, Russ.

In: Environment International, Vol. 95, 10.2016, p. 120-30.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Nassan, FL, Coull, BA, Skakkebaek, NE, Williams, MA, Dadd, R, Mínguez-Alarcón, L, Krawetz, SA, Hait, EJ, Korzenik, JR, Moss, AC, Ford, JB & Hauser, R 2016, 'A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease', Environment International, vol. 95, pp. 120-30. https://doi.org/10.1016/j.envint.2016.08.006

APA

Nassan, F. L., Coull, B. A., Skakkebaek, N. E., Williams, M. A., Dadd, R., Mínguez-Alarcón, L., Krawetz, S. A., Hait, E. J., Korzenik, J. R., Moss, A. C., Ford, J. B., & Hauser, R. (2016). A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease. Environment International, 95, 120-30. https://doi.org/10.1016/j.envint.2016.08.006

Vancouver

Nassan FL, Coull BA, Skakkebaek NE, Williams MA, Dadd R, Mínguez-Alarcón L et al. A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease. Environment International. 2016 Oct;95:120-30. https://doi.org/10.1016/j.envint.2016.08.006

Author

Nassan, Feiby L ; Coull, Brent A ; Skakkebaek, Niels E ; Williams, Michelle A ; Dadd, Ramace ; Mínguez-Alarcón, Lidia ; Krawetz, Stephen A ; Hait, Elizabeth J ; Korzenik, Joshua R ; Moss, Alan C ; Ford, Jennifer B ; Hauser, Russ. / A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease. In: Environment International. 2016 ; Vol. 95. pp. 120-30.

Bibtex

@article{813145d8549940429aec1cd1ba60d5f8,

title = "A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease",

abstract = "BACKGROUND: Phthalates are widely used chemicals with ubiquitous exposure. Dibutyl-phthalate (DBP), a male reproductive toxicant in animals, is understudied in humans. Some mesalamine medications used to treat inflammatory bowel disease (IBD) have DBP in their coating, whereas other mesalamine formulations do not.OBJECTIVES: Taking advantage of differences in mesalamine formulations, we investigated whether high-DBP exposure from mesalamine medications was associated with decreased semen parameters.METHODS: 73 men with IBD taking mesalamine participated in a crossover-crossback prospective study. Men taking non-DBP containing mesalamine at baseline i.e., background exposure, crossed-over for four months to high-DBP mesalamine and then crossed-back for four months to their non-DBP mesalamine (B1HB2-arm;Background1-High-Background2) and vice versa for men taking high-DBP mesalamine at baseline (H1BH2-arm;High1-Background-High2). Men provided up to six semen samples (2: baseline, 2: crossover and 2: crossback).RESULTS: We estimated crossover, crossback and carryover effects using linear mixed models adjusted for abstinence time, age, season and duration on high-DBP mesalamine at baseline. Semen parameters in B1HB2-arm (26 men, 133 samples) decreased after high-DBP mesalamine exposure (crossover versus baseline), especially motility parameters, and continued to decrease further even after crossback to non-DBP mesalamine (crossback versus crossover). The cumulative carryover effect of high-DBP (crossback versus baseline) was a decrease of % total sperm motility by 7.61(CI:-13.1, -2.15), % progressive sperm motility by 4.23(CI:-8.05, -0.4) and motile sperm count by 26.0% (CI:-46.2%, 1.7%). However, H1BH2-arm (47 men, 199 samples) had no significant change during crossover or crossback.CONCLUSIONS: Men newly exposed to high-DBP mesalamine for four months had a cumulative reduction in several semen parameters, primarily sperm motility, that was more pronounced and statistically significant even after exposure ended for four months.",

keywords = "Journal Article",

author = "Nassan, {Feiby L} and Coull, {Brent A} and Skakkebaek, {Niels E} and Williams, {Michelle A} and Ramace Dadd and Lidia M{\'i}nguez-Alarc{\'o}n and Krawetz, {Stephen A} and Hait, {Elizabeth J} and Korzenik, {Joshua R} and Moss, {Alan C} and Ford, {Jennifer B} and Russ Hauser",

year = "2016",

month = oct,

doi = "10.1016/j.envint.2016.08.006",

language = "English",

volume = "95",

pages = "120--30",

journal = "Environment international",

issn = "0160-4120",

publisher = "Pergamon Press",

}

RIS

TY - JOUR

T1 - A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease

AU - Nassan, Feiby L

AU - Coull, Brent A

AU - Skakkebaek, Niels E

AU - Williams, Michelle A

AU - Dadd, Ramace

AU - Mínguez-Alarcón, Lidia

AU - Krawetz, Stephen A

AU - Hait, Elizabeth J

AU - Korzenik, Joshua R

AU - Moss, Alan C

AU - Ford, Jennifer B

AU - Hauser, Russ

PY - 2016/10

Y1 - 2016/10

N2 - BACKGROUND: Phthalates are widely used chemicals with ubiquitous exposure. Dibutyl-phthalate (DBP), a male reproductive toxicant in animals, is understudied in humans. Some mesalamine medications used to treat inflammatory bowel disease (IBD) have DBP in their coating, whereas other mesalamine formulations do not.OBJECTIVES: Taking advantage of differences in mesalamine formulations, we investigated whether high-DBP exposure from mesalamine medications was associated with decreased semen parameters.METHODS: 73 men with IBD taking mesalamine participated in a crossover-crossback prospective study. Men taking non-DBP containing mesalamine at baseline i.e., background exposure, crossed-over for four months to high-DBP mesalamine and then crossed-back for four months to their non-DBP mesalamine (B1HB2-arm;Background1-High-Background2) and vice versa for men taking high-DBP mesalamine at baseline (H1BH2-arm;High1-Background-High2). Men provided up to six semen samples (2: baseline, 2: crossover and 2: crossback).RESULTS: We estimated crossover, crossback and carryover effects using linear mixed models adjusted for abstinence time, age, season and duration on high-DBP mesalamine at baseline. Semen parameters in B1HB2-arm (26 men, 133 samples) decreased after high-DBP mesalamine exposure (crossover versus baseline), especially motility parameters, and continued to decrease further even after crossback to non-DBP mesalamine (crossback versus crossover). The cumulative carryover effect of high-DBP (crossback versus baseline) was a decrease of % total sperm motility by 7.61(CI:-13.1, -2.15), % progressive sperm motility by 4.23(CI:-8.05, -0.4) and motile sperm count by 26.0% (CI:-46.2%, 1.7%). However, H1BH2-arm (47 men, 199 samples) had no significant change during crossover or crossback.CONCLUSIONS: Men newly exposed to high-DBP mesalamine for four months had a cumulative reduction in several semen parameters, primarily sperm motility, that was more pronounced and statistically significant even after exposure ended for four months.

AB - BACKGROUND: Phthalates are widely used chemicals with ubiquitous exposure. Dibutyl-phthalate (DBP), a male reproductive toxicant in animals, is understudied in humans. Some mesalamine medications used to treat inflammatory bowel disease (IBD) have DBP in their coating, whereas other mesalamine formulations do not.OBJECTIVES: Taking advantage of differences in mesalamine formulations, we investigated whether high-DBP exposure from mesalamine medications was associated with decreased semen parameters.METHODS: 73 men with IBD taking mesalamine participated in a crossover-crossback prospective study. Men taking non-DBP containing mesalamine at baseline i.e., background exposure, crossed-over for four months to high-DBP mesalamine and then crossed-back for four months to their non-DBP mesalamine (B1HB2-arm;Background1-High-Background2) and vice versa for men taking high-DBP mesalamine at baseline (H1BH2-arm;High1-Background-High2). Men provided up to six semen samples (2: baseline, 2: crossover and 2: crossback).RESULTS: We estimated crossover, crossback and carryover effects using linear mixed models adjusted for abstinence time, age, season and duration on high-DBP mesalamine at baseline. Semen parameters in B1HB2-arm (26 men, 133 samples) decreased after high-DBP mesalamine exposure (crossover versus baseline), especially motility parameters, and continued to decrease further even after crossback to non-DBP mesalamine (crossback versus crossover). The cumulative carryover effect of high-DBP (crossback versus baseline) was a decrease of % total sperm motility by 7.61(CI:-13.1, -2.15), % progressive sperm motility by 4.23(CI:-8.05, -0.4) and motile sperm count by 26.0% (CI:-46.2%, 1.7%). However, H1BH2-arm (47 men, 199 samples) had no significant change during crossover or crossback.CONCLUSIONS: Men newly exposed to high-DBP mesalamine for four months had a cumulative reduction in several semen parameters, primarily sperm motility, that was more pronounced and statistically significant even after exposure ended for four months.

KW - Journal Article

U2 - 10.1016/j.envint.2016.08.006

DO - 10.1016/j.envint.2016.08.006

M3 - Journal article

C2 - 27575365

VL - 95

SP - 120

EP - 130

JO - Environment international

JF - Environment international

SN - 0160-4120

ER -

ID: 176451950

Forskning